High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breast Cancer
Public ClinicalTrials.gov record NCT06538389. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
High Cannabidiol (CBD) Standardized Extract for Aromatase Inhibitor-Induced Arthralgia - A Randomized Controlled Double Blind Clinical Trial
Study identification
- NCT ID
- NCT06538389
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 36 participants
Conditions and interventions
Conditions
- Anatomic Stage 0 Breast Cancer AJCC v8
- Anatomic Stage I Breast Cancer AJCC v8
- Anatomic Stage II Breast Cancer AJCC v8
- Anatomic Stage IIIA Breast Cancer AJCC v8
- Breast Adenocarcinoma
- Breast Ductal Carcinoma In Situ
- Estrogen Receptor-Positive Breast Carcinoma
- Progesterone Receptor-Positive Breast Carcinoma
Interventions
- BRC-001 Drug
- Biospecimen Collection Procedure
- Placebo Administration Drug
- Questionnaire Administration Other
Drug · Procedure · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 25, 2024
- Primary completion
- Jan 23, 2027
- Completion
- Jan 23, 2027
- Last update posted
- Apr 29, 2026
2024 – 2027
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope Medical Center | Duarte | California | 91010 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Anatomic Stage 0 Breast Cancer AJCC v8 trials
Other public records listing Anatomic Stage 0 Breast Cancer AJCC v8. Sorted by last update posted; newest first. Not a recommendation.
- NCT07699991: A Navigation Program to Improve Survivorship Support Service Participation Among Non-metastatic Breast Cancer Survivors Not yet recruiting
- NCT06297265: Manual Lymphatic Drainage Breast Massage in Breast Cancer Patients After Breast Conserving Surgery Recruiting
- NCT06401889: Enhancing Skin Appearance and Quality of Life in Breast Cancer Survivors on Aromatase Inhibitor Therapy Recruiting
- NCT05379153: Testing Laser Therapy for Treatment of Vaginal Dryness in Survivors of Breast Cancer, The Revitalize Trial Recruiting
- NCT06008158: Evaluation of a Once Per Day Regimen of Accelerated Partial Breast Irradiation for Improved Breast Appearance in Pts w/Low Risk, Hormone Responsive Brst Ca Active, not recruiting
- NCT07443943: A Dietary Supplement (Resistant Potato Starch) for Reducing Musculoskeletal Symptoms in Individuals Planning to Receive Aromatase Inhibitor Therapy, AIMSS-RPS Trial Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06538389, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 29, 2026 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06538389 live on ClinicalTrials.gov.